LTI-03 gets FDA Fast Track status as Rein heads toward Phase 2 IPF data
FDA grants LTI-03 Fast Track status as Rein advances its 120-patient Phase 2 IPF trial toward a closely watched second-half 2026 readout.
Pharma & Biotech